Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7454578 | 1.00 | MAPT (0.44) | MAPTGAARAB9ASMN1; SMN2LMNA | |
| SCHEMBL10493472 | 0.90 | MAPT (0.41) | MAPTGAARAB9ASMN1; SMN2LMNA | |
| SCHEMBL10493466 | 0.90 | MAPT (0.41) | MAPTGAARAB9ASMN1; SMN2LMNA | |
| SCHEMBL11176703 | 0.85 | MAPT (0.41) | MAPTGAARAB9ASMN1; SMN2LMNA | |
| SCHEMBL11176701 | 0.85 | MAPT (0.41) | MAPTGAARAB9ASMN1; SMN2LMNA | |
| SCHEMBL11368203 | 0.83 | ALDH1A1 (0.45) | GAARAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL11368200 | 0.83 | ALDH1A1 (0.45) | GAARAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL11355028 | 0.83 | KDM4E (0.52) | MAPTSMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL11355023 | 0.83 | KDM4E (0.52) | MAPTSMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL11351129 | 0.82 | MAPT (0.49) | MAPTGAARAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114531850-B | Pharmaceutical composition and kit characterized by containing novel penicillin derivative or salt thereof and at least 1 compound selected from beta-lactamase inhibitory compound and antibacterial compound or salt thereof | 富士胶片株式会社 | 2024-08-06 | — | — | CN | disclosed |
| CN-111954673-B | New penam derivatives or salts thereof, pharmaceutical compositions and uses thereof | 富士胶片株式会社 | 2023-09-05 | — | — | CN | disclosed |
| CN-114531850-A | Pharmaceutical composition and kit characterized by containing novel penicillin derivative or salt thereof and 1 or more compounds selected from beta-lactamase inhibitory compound and antibacterial compound or salt thereof | 富士胶片株式会社 | 2022-05-24 | — | — | CN | disclosed |
| WO-2021066149-A1 | PHARMACEUTICAL COMPOSITION AND KIT CHARACTERIZED BY CONTAINING NOVEL PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM Β-LACTAMASE INHIBITOR COMPOUND, ANTIBACTERIAL COMPOUND AND SALTS OF THESE | 富士フイルム株式会社 | 2021-04-08 | — | — | WO | disclosed |
| US-20210024543-A1 | NOVEL PENAM DERIVATIVE OR SALT THEREOF, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2021-01-28 | — | — | US | disclosed |
| CN-111954673-A | Novel penam derivative or salt thereof, pharmaceutical composition, and use thereof | 富士胶片株式会社 | 2020-11-17 | — | — | CN | disclosed |
| WO-2019194306-A1 | NOVEL PENAM DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | 富士フイルム株式会社 | 2019-10-10 | — | — | WO | disclosed |
| WO-2019194306-A1 | NOVEL PENAM DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | 富士フイルム株式会社 | 2019-10-10 | — | — | WO | disclosed |
| EP-0891976-B1 | Novel cyclic ureas useful as antiarrhythmic and antifibrillatory agents | PROCTER & GAMBLE PHARMA (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6083945-A | USEFUL IN TREATING HUMANS OR OTHER MAMMALS WITH CARDIAC ARRHYTHMIA AND/OR CARDIAC FIBRILLATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0598046-B1 | CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMA (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0891976-A1 | Novel cyclic ureas useful as antiarrhythmic and antifibrillatory agents | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0598046-A1 | NOVEL CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-05-25 | — | — | EP | disclosed |
| WO-1993004060-A1 | NOVEL CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
| US-4099001-A | [[[Imidazolidinyl amino]carbonyl]amino]acetyl cephalosporin derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024543-A1 | NOVEL PENAM DERIVATIVE OR SALT THEREOF, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS THEREOF | CFTR, SLC11A2, SLC20A1 | MAPT 1941/4885GAA 366/4885RAB9A 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.